Results 71 to 80 of about 2,540 (169)

Inclisiran Sodium

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis

BMC Cardiovascular Disorders
Objective Hyperlipidemia plays a crucial role in increasing the risk of cardiovascular diseases such as atherosclerosis. Recent studies have established that inclisiran positively influences lipid regulation. Nevertheless, its effectiveness in comparison
Shengxuan Zhang, Lei Sun, Xinyu Xu, Yanling Zhang, Qilan Chen   +4 more
doaj   +1 more source

Idiosyncratic Drug-Induced Liver Injury in a Healthy Patient following PCSK9-Inhibitor Injection

Case Reports in Hepatology
Background. Acute liver injury is a life-threatening condition with disparate aetiology. Swift and adequate interdisciplinary treatment is essential to assure the best possible outcomes in these patients.
B.-O. Stüben, D. P. Hoyer, S. Radunz, F. Saner, H. Schmidt, H. A. Baba, J. W. Treckmann, L. I. Mazilescu   +7 more
doaj   +1 more source

Estimating the effect of inclisiran on hypercholesterolemia and primary prevention of cardiovascular disease: the NHANES 1999–2018 study

Lipids in Health and Disease
Background Hypercholesterolemia has been identified as an independent predictor of cardiovascular disease (CVD). Inclisiran, an innovative small interfering RNA agent, is anticipated to result in a notable reduction of approximately 50% in low-density ...
Haonan Li, Song Zhao, Jiawen Wu, Jun Han, Yawei Xu, Shengfeng Shi, Yi Zhang   +6 more
doaj   +1 more source

The Role of PCSK9 Inhibition and Small Interference RNA (siRNA) in The Management of Dyslipidaemia and ASCVD

Indonesian Biomedical Journal
Compelling evidence linking low-density lipoprotein cholesterol (LDL-C) reduction to decreased mortality has positioned LDL-C lowering as a central strategy in the prevention of atherosclerotic cardiovascular disease (ASCVD).
Anwar Santoso, Bambang Dwiputra
doaj   +1 more source

First Russian experience of treating dyslipidemia with siRNA drugs in patients after heart transplantation

Российский кардиологический журнал
Patients after heart transplantation (HT) are at very high risk for cardiovascular disease. Protocols for the management of heart recipients include the initiation of lipid-lowering therapy (LLT), regardless of sex, age and origin of heart failure. Given
M. A. Simonenko, A. S. Alieva, M. Yu. Sitnikova, P. A. Fedotov   +3 more
doaj   +1 more source

Hypolypidemic therapy in the XXI century: what is new?

RUDN Journal of Medicine
Relevance. The leading position in mortality throughout the world is occupied by cardiovascular diseases, caused be atherosclerosis process. Statins used to be the gold standard of lipid-lowering therapy for a long time due to their high efficacy ...
Natalya Yu. Ob’edkova, Diana N. Usacheva, Galina S. Mal, Evgenij G. Ob’edkov   +3 more
doaj   +1 more source

A Real-World Retrospective Analysis of Secondary Prevention Patients Treated with Inclisiran over 27 Months

Clinical Medicine Insights: Cardiology
ASCVD is a global concern as it has become central to significant morbidity and mortality. LDL-C is the most important modifiable risk factor in developing ASCVD.
Carl Deaney, Meredith Donaldson, Agne Meskauskiene   +2 more
doaj   +1 more source

The Effects of Inclisiran on the Subclinical Inflammatory Markers of Atherosclerotic Cardiovascular Disease in Patients at High Cardiovascular Risk

Pharmaceuticals
Background/Objectives: Hypercholesterolemia, accompanied by vascular inflammation, leads to the premature initiation and progression of atherosclerosis, and both are considered nowadays as well-established cardiovascular (CV) risk factors.
Mateusz Maligłówka, Adrianna Dec, Łukasz Bułdak, Bogusław Okopień   +3 more
doaj   +1 more source

(Inclisiran - the first experiences)

Cor et Vasa, 2023
Michaela Štroffeková, Jana Obrová, Miloš Táborský   +2 more
openaire   +1 more source